| Expression pattern: |
UP |
| Associated gene: |
FGF9, reactive oxygen species, GSH, SOD |
| Associated microRNA: |
miR-187-3p |
| Biological function: |
circCCND1 promotes NSCLC progression and cisplatin chemoresistance, enhances cell viability and proliferation under cisplatin treatment, and suppresses apoptosis; circCCND1 knockdown sensitizes NSCLC cells to cisplatin treatment. |
| Molecular mechanism: |
circCCND1 functions through a ceRNA-like mechanism by sponging/interacting with miR-187-3p to regulate reactive oxygen species and FGF9 in NSCLC cells, thereby enhancing cisplatin resistance. |
| Biological pathway or process: |
drug resistance (promotes); chemoresistance (promotes); proliferation (promotes); apoptosis (inhibits); ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; MTT; Colony Formation Assay; TUNEL; Transfection; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
circCCND1 is elevated in lung tumors, higher circCCND1 expression is associated with advanced stages, and high circCCND1 expression predicts poorer overall survival. |
| Description: |
circCCND1 is up-regulated in NSCLC cells and lung tumor datasets and is associated with advanced stage and poorer survival. Functionally, circCCND1 promotes cisplatin chemoresistance by sustaining NSCLC cell viability/proliferation and inhibiting apoptosis. Mechanistically, it acts through a miR-187-3p/ROS/FGF9 axis. |
| Confidence score: |
0.6415 |